menu
    • menu
    [{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series C Financing","leadProduct":"ENV-294","moa":"JAK","graph1":"Dermatology","graph2":"Phase I","graph3":"Enveda Bioscience","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Enveda Bioscience \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Enveda Bioscience \/ Sanofi"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ENV-294","moa":"JAK","graph1":"Dermatology","graph2":"Phase I","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveda Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enveda Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ENV-294","moa":"JAK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveda Bioscience \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Premji Invest","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series D Financing","leadProduct":"ENV-294","moa":"JAK","graph1":"Dermatology","graph2":"Phase I","graph3":"Enveda Bioscience","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.14999999999999999,"dosageForm":"Pill","sponsorNew":"Enveda Bioscience \/ Premji Invest","highestDevelopmentStatusID":"6","companyTruncated":"Enveda Bioscience \/ Premji Invest"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Kinnevik AB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Enveda Bioscience","amount2":0.12,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"Spray, Metered","sponsorNew":"Enveda Bioscience \/ Kinnevik AB","highestDevelopmentStatusID":"2","companyTruncated":"Enveda Bioscience \/ Kinnevik AB"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Microsoft","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveda Bioscience \/ Microsoft","highestDevelopmentStatusID":"3","companyTruncated":"Enveda Bioscience \/ Microsoft"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Premji Invest","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Enveda Bioscience \/ Premji Invest","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bioscience \/ Premji Invest"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Lux Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Enveda Bioscience","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Enveda Bioscience \/ Lux Capital","highestDevelopmentStatusID":"3","companyTruncated":"Enveda Bioscience \/ Lux Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Enveda Bioscience

    Menu

    Enveda Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ENV-294

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Premji Invest

                            Deal Size : $150.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Enveda Raises $150M Series D Funding to Reach Unicorn Status

                            Details : The Series D funding will advance multiple clinical programs, including ENV-294, a first-in-class, oral anti-inflammatory small molecule, in atopic dermatitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 04, 2025

                            Lead Product(s) : ENV-294

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Premji Invest

                            Deal Size : $150.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ENV-294

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enveda Reports Phase 1 Safety and Starts Phase 1B Trial in Atopic Dermatitis

                            Details : ENV-294 is a first-in-class, oral small molecule, JAK-inhibitor therapeutic being investigated for atopic dermatitis, asthma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 28, 2025

                            Lead Product(s) : ENV-294

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ENV-294

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Sanofi

                            Deal Size : $150.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Enveda Gains Sanofi Backing to Advance AI Drug Discovery, Raising Series C to $150M

                            Details : The financing aims to advance the development of company's pipeline, which includes ENV-294, a first-in-class, oral small molecule, with JAK-inhibitor. It is being evaluated for Atopic Dermatitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 26, 2025

                            Lead Product(s) : ENV-294

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Sanofi

                            Deal Size : $150.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ENV-294

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enveda Moves into Asthma with ENV-294 and Assembles Expert Advisory Board

                            Details : ENV-294 is a first-in-class, oral small molecule, with JAK-inhibitor-like efficacy and IL4/IL13-like safety, targeting asthma and other inflammatory conditions.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 05, 2025

                            Lead Product(s) : ENV-294

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Premji Invest

                            Deal Size : $119.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Enveda Biosciences Announces $55M in New Funding to Advance Candidates to Clinical Trials

                            Details : The new funding will support further development of Enveda’s breakthrough platform, including Enveda's lead program for atopic dermatitis, a novel oral first-in-class anti-inflammatory agent.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 14, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Premji Invest

                            Deal Size : $119.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Microsoft

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Enveda Biosciences Announces Microsoft Collaboration for Chemistry Translation

                            Details : The collaboration with Microsoft includes access to compute resources needed to power Enveda’s natural product drug discovery and its evolution into a clinical-stage company.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 29, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Microsoft

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Sponsor : Kinnevik AB

                            Deal Size : $119.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million

                            Details : Enveda will use the net financing to progress multiple platform-derived molecules to the clinic in 2023 and 2024 across inflammation, fibrosis, and neurosensory indications.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Sponsor : Kinnevik AB

                            Deal Size : $119.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Enveda Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery Platform

                            Sponsor : Lux Capital

                            Deal Size : $51.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Enveda Biosciences Closes $51M Series A Financing Led by Lux Capital

                            Details : Enveda’s platform is the world’s most advanced drug discovery search engine for dark chemical space, building on years of cutting-edge advancements at the intersection of metabolomics and machine learning.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 22, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery Platform

                            Sponsor : Lux Capital

                            Deal Size : $51.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth